Our DMPK team is having expertise in both integrated drug discovery and standalone DMPK services with experience over 16 years. Our capabilities helped us to deliver more than 65 IDD projects. We design customized protocols and perform assays based on client or project requirements. The DMPK facility spanning an area of 10,000 sq.ft. in Bangalore and Hyderabad locations consists of state-of-the-art in vitro ADME and tissue culture labs, AAALAC accredited animal facility for in vivo PK studies in rats, mice & dogs and GLP & Non-GLP bioanalytical labs with high-end LC-MS/MS instruments.
In vitro ADME capable of high-throughput screening with best in industry turnaround times. In vivo PK studies with various established surgical models. Experience in DMPK studies and bioanalysis of small molecules, PROTACs, therapeutic peptides and biomarkers. Automated compound management and data handling systems.
Turnaround time: In vitro Assays: 5 working days. In vivo PK Studies: 7 working days
Quality & accuracy
Compound management and data automation
Broad panel of in vitro ADME & in vivo PK study designs
Bioanalysis of small molecules, therapeutic peptides, biomarkers and complex molecules. Delivered 200+ GLP studies
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
ADME data helps scientists assess and optimize the absorption, distribution, metabolism, and excretion of the drug/NCE early in the drug discovery process. This helps to minimize late-stage failures in in-vivo safety and efficacy studies and clinical trials.
ADME testing involves various in-vitro and in-vivo assays used to assess the properties that determine the Absorption, Distribution, Metabolism, and Excretion (ADME) of NCEs/ drug molecules.
The ADME process involves the characterization of a drug by using different assays to determine its absorption, distribution, metabolism, and excretion properties. This data is critical to prioritize and advance drug/ NCEs for future development.
DMPK is the study of the drug-like properties of new chemical entities(NCE)/drugs to understand its metabolism and pharmacokinetic profile.
PK studies are an integral part of drug development. It helps to understand a new chemical entity (NCEs)/drug's pharmacokinetic behaviour in the body and involves the study of distribution, metabolism, clearance and bioavailability.
Pharmacokinetics (PK) is the response of the body to the drug. Whereas Pharmacodynamics (PD) is the action of the drug on our body.
For a period of 6 weeks, Oligos can be stored in T10E1 buffer at 37°C and for the long term, Oligonucleotides can be dried down and stored with or without TE buffer at -20°C.
Pharmacodynamics (PD) of a drug refers to the biochemical and physiological effects caused by the drug/NCE in the body.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.